Clinical pharmacokinetics of toremifene

Tracy L. Taras, Gregory T. Wurz, Gabriel R. Linares, Michael W. DeGregorio

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Toremifene is a chlorinated triphenylethylene derivative of tamoxifen approved for use in the treatment of patients with metastatic breast cancer. Toremifene is well tolerated in patients, and common adverse effects of this drug include vasomotor symptoms such as hot flashes and vaginal discharge. This compound is administered to patients orally at a dose of 60 mg/day, although alternative methods of administration have been investigated. Oral bioavailability is estimated to be approximately 100%. At steady state, toremifene and its metabolites are highly protein bound (>95%). Toremifene is metabolised in the liver by cytochrome P450 enzymes, and it is eliminated primarily in the faeces following enterohepatic circulation. The half-life of toremifene is approximately 5 days, and steady state is reached by 6 weeks depending on the dose given. The pharmacokinetics of toremifene have been shown to be altered by certain liver conditions, but age and kidney function do not appear to be as significant.

Original languageEnglish (US)
Pages (from-to)327-334
Number of pages8
JournalClinical Pharmacokinetics
Volume39
Issue number5
StatePublished - 2000

Fingerprint

Toremifene
Pharmacokinetics
Cytochrome P-450 Enzyme System
Hot Flashes
Enterohepatic Circulation
Vaginal Discharge
Liver
Tamoxifen
Feces
Biological Availability
Half-Life
Breast Neoplasms
Kidney
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Taras, T. L., Wurz, G. T., Linares, G. R., & DeGregorio, M. W. (2000). Clinical pharmacokinetics of toremifene. Clinical Pharmacokinetics, 39(5), 327-334.

Clinical pharmacokinetics of toremifene. / Taras, Tracy L.; Wurz, Gregory T.; Linares, Gabriel R.; DeGregorio, Michael W.

In: Clinical Pharmacokinetics, Vol. 39, No. 5, 2000, p. 327-334.

Research output: Contribution to journalArticle

Taras, TL, Wurz, GT, Linares, GR & DeGregorio, MW 2000, 'Clinical pharmacokinetics of toremifene', Clinical Pharmacokinetics, vol. 39, no. 5, pp. 327-334.
Taras TL, Wurz GT, Linares GR, DeGregorio MW. Clinical pharmacokinetics of toremifene. Clinical Pharmacokinetics. 2000;39(5):327-334.
Taras, Tracy L. ; Wurz, Gregory T. ; Linares, Gabriel R. ; DeGregorio, Michael W. / Clinical pharmacokinetics of toremifene. In: Clinical Pharmacokinetics. 2000 ; Vol. 39, No. 5. pp. 327-334.
@article{bc4d6109141b4b66a5941058cbff1169,
title = "Clinical pharmacokinetics of toremifene",
abstract = "Toremifene is a chlorinated triphenylethylene derivative of tamoxifen approved for use in the treatment of patients with metastatic breast cancer. Toremifene is well tolerated in patients, and common adverse effects of this drug include vasomotor symptoms such as hot flashes and vaginal discharge. This compound is administered to patients orally at a dose of 60 mg/day, although alternative methods of administration have been investigated. Oral bioavailability is estimated to be approximately 100{\%}. At steady state, toremifene and its metabolites are highly protein bound (>95{\%}). Toremifene is metabolised in the liver by cytochrome P450 enzymes, and it is eliminated primarily in the faeces following enterohepatic circulation. The half-life of toremifene is approximately 5 days, and steady state is reached by 6 weeks depending on the dose given. The pharmacokinetics of toremifene have been shown to be altered by certain liver conditions, but age and kidney function do not appear to be as significant.",
author = "Taras, {Tracy L.} and Wurz, {Gregory T.} and Linares, {Gabriel R.} and DeGregorio, {Michael W.}",
year = "2000",
language = "English (US)",
volume = "39",
pages = "327--334",
journal = "Clinical Pharmacokinetics",
issn = "0312-5963",
publisher = "Adis International Ltd",
number = "5",

}

TY - JOUR

T1 - Clinical pharmacokinetics of toremifene

AU - Taras, Tracy L.

AU - Wurz, Gregory T.

AU - Linares, Gabriel R.

AU - DeGregorio, Michael W.

PY - 2000

Y1 - 2000

N2 - Toremifene is a chlorinated triphenylethylene derivative of tamoxifen approved for use in the treatment of patients with metastatic breast cancer. Toremifene is well tolerated in patients, and common adverse effects of this drug include vasomotor symptoms such as hot flashes and vaginal discharge. This compound is administered to patients orally at a dose of 60 mg/day, although alternative methods of administration have been investigated. Oral bioavailability is estimated to be approximately 100%. At steady state, toremifene and its metabolites are highly protein bound (>95%). Toremifene is metabolised in the liver by cytochrome P450 enzymes, and it is eliminated primarily in the faeces following enterohepatic circulation. The half-life of toremifene is approximately 5 days, and steady state is reached by 6 weeks depending on the dose given. The pharmacokinetics of toremifene have been shown to be altered by certain liver conditions, but age and kidney function do not appear to be as significant.

AB - Toremifene is a chlorinated triphenylethylene derivative of tamoxifen approved for use in the treatment of patients with metastatic breast cancer. Toremifene is well tolerated in patients, and common adverse effects of this drug include vasomotor symptoms such as hot flashes and vaginal discharge. This compound is administered to patients orally at a dose of 60 mg/day, although alternative methods of administration have been investigated. Oral bioavailability is estimated to be approximately 100%. At steady state, toremifene and its metabolites are highly protein bound (>95%). Toremifene is metabolised in the liver by cytochrome P450 enzymes, and it is eliminated primarily in the faeces following enterohepatic circulation. The half-life of toremifene is approximately 5 days, and steady state is reached by 6 weeks depending on the dose given. The pharmacokinetics of toremifene have been shown to be altered by certain liver conditions, but age and kidney function do not appear to be as significant.

UR - http://www.scopus.com/inward/record.url?scp=0033678649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033678649&partnerID=8YFLogxK

M3 - Article

C2 - 11108432

AN - SCOPUS:0033678649

VL - 39

SP - 327

EP - 334

JO - Clinical Pharmacokinetics

JF - Clinical Pharmacokinetics

SN - 0312-5963

IS - 5

ER -